TY - JOUR
T1 - Accelerated healing of diabetic wounds by NorLeu3-angiotensin (1-7)
AU - Rodgers, Kathleen
AU - Verco, Shelagh
AU - Bolton, Laura
AU - Dizerega, Gere
N1 - Funding Information:
K Rodgers is an inventor on patents covering this peptide and may have royalties associated. She was the principal investigator on the SBIR grant that funded much of the work. S Verco was the project manager for a clinical trial for US Biotest. G diZerega is an inventor on patents covering this peptide and may have royalties associated. He is the owner of the company that received the SBIR grant that funded much of the work.This work was supported by NIHSBIR grant 5 R44DK076425. DermaSciences supported the clinical trial in part.
PY - 2011/11
Y1 - 2011/11
N2 - Introduction: Diabetes is a disorder that is well known to delay wound repair resulting in the formation of colonized, chronic wounds. The resultant ulcers contribute to increased risk of morbidity, including osteomyelitis and amputations, and increased burden to the healthcare system. Areas covered: The only active product approved for the treatment of diabetic ulcers, Regranex, has been shown to reduce amputation risk, but is not widely used due to minimal proven efficacy and recent warnings added to the Instructions for Use. This review provides an overview of the development of NorLeu3-angiotensin (1-7) (NorLeu3-A(1-7)) as an active agent for the treatment of diabetic wounds. NorLeu3-A(1-7) is an analog of the naturally occurring peptide, angiotensin 1-7. The mechanisms of action include induction of progenitor proliferation and accelerated vascularization, collagen deposition and re-epithelialization. Expert opinion: Research to date has shown that NorLeu3-A(1-7) is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. Further clinical development of this product as a topical agent for the healing of chronic wounds and investigation into the mechanisms by which this product accelerates healing are warranted.
AB - Introduction: Diabetes is a disorder that is well known to delay wound repair resulting in the formation of colonized, chronic wounds. The resultant ulcers contribute to increased risk of morbidity, including osteomyelitis and amputations, and increased burden to the healthcare system. Areas covered: The only active product approved for the treatment of diabetic ulcers, Regranex, has been shown to reduce amputation risk, but is not widely used due to minimal proven efficacy and recent warnings added to the Instructions for Use. This review provides an overview of the development of NorLeu3-angiotensin (1-7) (NorLeu3-A(1-7)) as an active agent for the treatment of diabetic wounds. NorLeu3-A(1-7) is an analog of the naturally occurring peptide, angiotensin 1-7. The mechanisms of action include induction of progenitor proliferation and accelerated vascularization, collagen deposition and re-epithelialization. Expert opinion: Research to date has shown that NorLeu3-A(1-7) is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. Further clinical development of this product as a topical agent for the healing of chronic wounds and investigation into the mechanisms by which this product accelerates healing are warranted.
KW - Angiotensin
KW - Dermal
KW - Diabetes
KW - NorLeu3-angiotensin 1-7
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=80053987489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053987489&partnerID=8YFLogxK
U2 - 10.1517/13543784.2011.619976
DO - 10.1517/13543784.2011.619976
M3 - Review article
C2 - 21973177
AN - SCOPUS:80053987489
VL - 20
SP - 1575
EP - 1581
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 11
ER -